Therapeutic options for herpes simplex infections

Current Infectious Disease Reports

Volumn 5, Issue 1, 2003, Pages 22-27

  Au, Eugene ^a   Sacks, Stephen L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; ACICLOVIR; ANTIVIRUS AGENT; BEHENYL ALCOHOL; CIDOFOVIR; DNA POLYMERASE; FAMCICLOVIR; FOSCARNET; HERPES SIMPLEX VACCINE; PENCICLOVIR; PHOSPHORYL LIPID A; RESIQUIMOD; SULFONIC ACID DERIVATIVE; THIAZOLE DERIVATIVE; UREA DERIVATIVE; VALACICLOVIR; VIRUS DNA;

CLINICAL TRIAL; CYTOKINE PRODUCTION; DNA REPAIR; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVATION; GASTROINTESTINAL SYMPTOM; GENITAL ULCER; HERPES SIMPLEX; HUMAN; HYPOCALCEMIA; IMMUNE RESPONSE; INFECTION CONTROL; KIDNEY DISEASE; RECURRENT DISEASE; REVIEW;

EID: 3142632127     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-003-0061-3     Document Type: Review

References (49)

1. Sacks SL: The Truth About Herpes, 4th edn. West Vancouver, Canada: Gordon Soules Book Publishers Ltd; 1997.
2. Yeung-Yue KA, Brentjens MH, Lee PC, Tyring SK: The management of herpes simplex virus infections. Curr Opin Infect Dis 2002, 15:115-122.
3. Sacks SL: Improving the management of genital herpes. Hosp Pract 1999, 34:41-49.
4. Armstrong GL, Schillinger J, Markowitz L, et al.: Incidence of herpes simplex virus type 2 infection in the United States. Am J Epidemoiol 2001, 153:912-920.
5. Whitley RJ, Roizman B: Herpes simplex infections. Lancet 2001, 357:1513-1518.
6. Derse D, Cheng Y-C, Furman PA, et al.: Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyehoxymethyl) guanine triphosphate: effects on primer-template function. J Biol Chem 1981, 256:11447-11451.
7. Leung DT, Sacks SL: Current recommendations for the treatment of genital herpes. Drugs 2000, 60:1329-1352.
8. Centers for Disease Control and Prevention: Sexually Transmitted Diseases Treatment Guidelines 2002. http://www.cdc.gov/std/treatment/2-2002TG.htm. Accessed October 21, 2002.
9. Wald A, Carrell D, Remington M, et al.: Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002, 34:944-948.
10. Douglas JM, Critchlow C, Benedetti J, et al.: A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984, 310:1551-1556.
11. Straus SE, Croen KD, Sawyer MH, et al.: Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment. JAMA 1988, 260:2227-2230.
12. Spruance SL, Stewart JC, Rowe NH, et al.: Treatment of recurrent herpes simplex labialis with oral acyclovir. J Infect Dis 1990, 161:185-190.
13. Spruance SL: Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis. J Med Virol 1993, 1(Suppl):27-32.
14. Rooney JF, Straus SE, Mannix ML, et al.: Oral acyclovir to suppress frequently recurrent herpes labialis: a double-blind, placebo-controlled trial. Ann Intern Med 1993, 118:268-272.
15. Weller S, Blum MR, Doucette M, et al.: Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-dose and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993, 54:595-605.
16. Reitano M, Tyring S, Lang W, et al.: Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998, 178:603-610.
17. Conant MA, Schacker TW, Murphy RL, et al.: Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 2002, 13:12-21.
18. Spruance SL, Jones TM, Blatter MM, et al.: Oral valaciclovir for the treatment of herpes labialis: two trials of early, high-dose, short-course therapy. In Program and Abstracts of the Fifteenth International Conference on Antiviral Research. Prague, Czech Republic; 2002:A53.
19. Corey L, Tyring S, Beutner K, et al.: Once daily valaciclovir reduces transmission of genital herpes. In Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego; 2002:LB9.
20. Earnshaw DL, Bacon TH, Darlison SJ, et al.: Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992, 36:2747-2757.
21. Loveless M, Sacks SL, Harris JRW: Famciclovir in the management of first-episode genital herpes. Infect Dis Clin Pract 1997, 6(Suppl 1):S12-S16.
22. Hill EL, Hunger GA, Ellis MN: In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1991, 35:2322-2328.
23. Chatis PA, Crumpacker CS: Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses. Virology 1991, 180:793-797.
24. Snoeck R: Antiviral therapy of herpes simplex. Int J Antimicrob Agents 2000, 16:157-159.
25. Jacobson MA: Review of the toxicities of foscarnet. J Acquir Immune Defic Syndr 1992, 5(Suppl 1):S11-S17.
26. Sacks SL, Shafran SD, Diaz-Mitoma F, et al.: A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes. Antimicrob Agents Chemother 1998, 42:2996-2999.
27. Lalezari J, Schacker T, Feinberg J, et al.: A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997, 176:892-898.
28. Koelle DM, Wald A: Herpes simplex virus: the importance of asymptomatic shedding. J Antimicrob Chemother 2000, 45:1-8.
29. Whitley RJ, Roizman B: Herpes simplex viruses: is a vaccine tenable? J Clin Invest 2002, 110:145-151.
30. Stanberry LR, Cunningham AL, Mindel A, et al.: Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000, 30:549-566.
31. Kaerner HC, Schroder CH, Ott-Hartmann A, et al.: Genetic variability of herpes simplex virus: development of a pathogenic variant during passaging of a nonpathogenic herpes simplex virus type 1 virus strain in mouse brain. J Virol 1983, 46:83-93.
32. Mertz GJ, Ashley R, Burke RL, et al.: Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 1990, 161:653-660.
33. Corey L, Langenberg AGM, Ashley R, et al.: Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 1999, 282:331-340.
34. Stanberry LR, Spruance SL, Cunningham AL, et al.: Glycoprotein-D - adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347:1652-1661.
35. Hemmi H, Kaisho T, Takeuchi O, et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002, 3:196-200.
36. Miller RL, Tomai MA, Harrison CJ, Bernstein DI: Immunomodulation as a treatment strategy for genital herpes: review of the evidence. Int Immunopharmacol 2002, 2:443-451.
37. Wagner TL, Ahonen CL, Couture AM, et al.: Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999, 191:10-19.
38. Ahonen CL, Gibson SJ, Smith RM, et al.: Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell Immunol 1999, 197:62-72.
39. Spruance SL, Tyring SK, Smith MH, Meng TC: Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis 2001, 184:196-200.
40. Pope LE, Marcelletti JF, Katz LR, et al.: The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antiviral Res 1998, 40:85-94.
41. Pope LE, Marcelletti JF, Katz LR, Katz DH: Anti-herpes simplex virus activity of n-docosanol correlates with intracellular metabolic conversion of the drug. J Lipid Res 1996, 32:2167-2178.
42. Sacks SL, Thisted RA, Jones TM, et al.: Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: a multicenter, randomized, placebo-controlled trial. J Am Acad Dermatol 2001, 45:222-230.
43. Zeitlin L, Whaley KJ: Microbicides for preventing transmission of genital herpes. Herpes 2002, 9:4-9.
44. Zeitlin L, Hoen TE, Achilles SL, et al.: Tests of buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis 2001, 28:417-423.
45. Bourne N, Bernstein DI, Ireland J, et al.: The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. J Infect Dis 1999, 180:203-205,
46. Snoeck R, De Clercq E: New treatments for genital herpes. Curr Opin Infect Dis 2002, 15:49-55.
47. Villarreal EC: Current and potential therapies for the treatment of herpesvirus infections. Prog Drug Res 2001, 56:77-120.
48. Kleymann G, Fischer R, Betz UAK, et al.: New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 2002, 8:392-398.
49. Crute JJ, Grygon CA, Hargrave KD, et al.: Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med 2002, 8:386-391.